- Record: found
- Abstract: found
- Article: not found
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Yutaka Ueda
1 ,
Takashi Miyatake ,
Masaaki Nagamatsu ,
Masato Yamasaki ,
Yukihiro Nishio ,
Kiyoshi Yoshino ,
Masami Fujita ,
Tateki Tsutsui ,
Takayuki Enomoto ,
Tadashi Kimura
Sep 2013
CR,
Clear cell,
Docetaxel,
Irinotecan,
MDCT,
Mucinous,
OS,
Ovarian cancer,
PD,
PFS,
PR,
RR,
Refractory,
Resistant,
SD,
TC,
TFI,
complete response,
multi-detector row computed tomography,
overall survival,
paclitaxel and carboplatin,
partial response,
progression-free survival,
progressive disease,
responsive rate,
stable disease,
treatment-free interval
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To analyze the efficacy and safety of combination chemotherapy of docetaxel and irinotecan for paclitaxel and carboplatin (TC) -refractory or -resistant ovarian carcinomas and for first treatment of primary clear cell and mucinous ovarian carcinomas.
Related collections
Author and article information
overall survival,Clear cell,Docetaxel,Irinotecan,MDCT,Mucinous,OS,Ovarian cancer,PD,PFS,PR,RR,Refractory,Resistant,SD,TC,TFI,complete response,multi-detector row computed tomography,paclitaxel and carboplatin,partial response,progression-free survival,progressive disease,responsive rate,stable disease,treatment-free interval,CR
overall survival, Clear cell, Docetaxel, Irinotecan, MDCT, Mucinous, OS, Ovarian cancer, PD, PFS, PR, RR, Refractory, Resistant, SD, TC, TFI, complete response, multi-detector row computed tomography, paclitaxel and carboplatin, partial response, progression-free survival, progressive disease, responsive rate, stable disease, treatment-free interval, CR